Sherene Loi, Medical Oncologist, Lab Head of Breast Oncology Clinical Trials at Peter MacCallum Cancer Centre, Australia, shared on X:
“Panku-breast01
Izabren sig. improves PFS in met HR+HER2 post CDK4i.
New targets, impressive ORR too. Broadly comparable to DB04 – here all HER2. But haem tox. Still have the what next issue Online publication in The Lancet Oncology.”
Title: Izalontamab brengitecan for HR+/HER2– breast cancer in
China (PANKU-Breast01): a randomised, phase 3 trial
Authors: Bo Lan, Yehui Shi, Xiying Shao, Fan Wu, Shusen Wang, Weimin Xie, Qingyuan Zhang, Quchang Ouyang, Jiuwei Cui, Xiaoling Ling, Haijun Yu, Huihui Li, Xianjun Tang, Sijuan Ding, Chunfang Hao, Bing Zhao, Yang Li, Hua Yang, Min Yan, Guohui Han, Xujuan Wang, Fanfan Li, Peijian Peng, Chang Gong, Yunjiang Liu, Junlan Guo, Yongmei Yin, Man Li, Yue’e Teng, Jiuda Zhao, Yongli Gao, Jingfen Wang, Jing Luo, Xinghua Han, Xiaoping Li, Bin Liu, Shuqun Zhang, Bihui Li, Lei Yang, Sa Xiao, Hai Zhu, Yi Zhu, Binghe Xu,
You can also read:
